All In Biotech

Drug Trial Radar · NCT07187895

Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis

Comparative Imaging Study of PET Myocardial Perfusion With XTR004 Injection Versus MIBI SPECT in Patients With Borderline Coronary Stenosis

Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

17

Actual

Start

Dec 19, 2024

Primary completion

Mar 5, 2025

Study completion Mar 5, 2025

Sponsor

Lead sponsor
Sinotau Pharmaceutical GroupIndustry
Sponsor type
Industry
First posted
Sep 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Compare the diagnostic certainty of MIBI SPECT myocardial perfusion imaging (MPI) and XTR004 PET MPI.

Conditions

  • Myocardial Perfusion Imaging
  • Diagnostic Certainty
  • Stable Coronary Artery Disease

Interventions

  • XTR004Drug

    At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of vessel-level diagnostic certainty for XTR004 PET/MIBI SPECT myocardial perfusion imaging.Time frame: Day1-7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.